Stockscreener 앱 받기
3.555
5.45%
-0.205
시장 영업 전:
3.94
0.385
+10.83%
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
Barclays PLC Acquires 61,317 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Decreases By 17.0% - MarketBeat
Jane Street Group LLC Sells 33,439 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Trevi Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Trevi Therapeutics stock target lifted, holds Buy on treatment progress By Investing.com - Investing.com Canada
What Makes Trevi Therapeutics (TRVI) a New Buy Stock - Yahoo Finance
Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Nasdaq
Trevi Therapeutics (TRVI) Stock Price, News & Analysis - MarketBeat
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com
Geode Capital Management LLC Increases Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Barclays PLC Raises Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $9.31 - Defense World
Trevi Therapeutics stock soars to 52-week high of $4.68 By Investing.com - Investing.com Australia
Trevi Therapeutics stock soars to 52-week high of $4.68 - Investing.com India
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
State Street Corp Has $3.18 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75% - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Large Increase in Short Interest - MarketBeat
Trevi Therapeutics Reports Second Quarter 2024 Financial Results - GuruFocus.com
BNP Paribas Financial Markets Purchases 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Cough in Idiopathic Pulmonary Pipeline Report 2024: Clinical Trials Progress and Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - The Eastern Progress Online
Trevi Therapeutics sets $50 million stock offering price By Investing.com - Investing.com Australia
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - The Eastern Progress Online
Form 424B5 Trevi Therapeutics, Inc. - StreetInsider.com
Trevi Therapeutics Prices of $50 Million Underwritten Offering - citybiz
Trevi Therapeutics sets $50 million stock offering price - Investing.com
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering - PR Newswire
Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $7.50 - Defense World
Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results - Stocks Telegraph
Institutional investors control 39% of Trevi Therapeutics, Inc. (NASDAQ:TRVI) and were rewarded last week after stock increased 38% - Simply Wall St
Trevi stock rockets on Haduvio study update - MSN
Trevi stock rockets on Haduvio study update (TRVI:NASDAQ) - Seeking Alpha
Trevi Therapeutics stock soars to 52-week high of $4.07 - Investing.com
Trevi Therapeutics Shares Hit 52-Week High After Positive Trial Analysis - MarketWatch
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? - Benzinga
Trevi Therapeutics, Inc. Announces Positive Outcome from Sample Size Re-Estimation Resulting in No Change to the Current Sample Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - Marketscreener.com
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - PR Newswire
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - The Eastern Progress Online
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.13 Consensus Target Price from Brokerages - Defense World
Trevi Therapeutics to Participate in September Investor and Medical Conferences - The Eastern Progress Online
HC Wainwright Has Negative Outlook of TRVI FY2024 Earnings - MarketBeat
4.81%
자본화:
|
볼륨(24시간):